Celltrion Healthcare Gears Up For Infliximab SC Launch
UK Commercial Head Reveals Strategy For Innovative Biosimilar Infliximab
As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.
You may also be interested in...
Celltrion says new data show that its Remsima SC subcutaneous infliximab biosimilar produces “statistically greater improvements in clinical outcomes” for rheumatoid arthritis patients compared to intravenous infliximab.
Celltrion has launched Remsima SC in the UK. Meanwhile, the innovative subcutaneous version of biosimilar infliximab has also received approval in Korea.
Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.